Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Tekmira Sues Alnylam Over Technology
by Michael McCoy
March 21, 2011
| A version of this story appeared in
Volume 89, Issue 12
Tekmira Pharmaceuticals is suing Alnylam Pharmaceuticals for misuse of trade secrets and confidential information related to Tekmira’s lipid nanoparticle siRNA delivery technology. Since 2007, Alnylam has been developing siRNA-based drugs that are delivered to the body using Tekmira’s technology. Among other things, Tekmira claims that Alnylam disclosed Tekmira manufacturing instructions to a third-party collaborator and included confidential information in patent filings. Tekmira claims it has rights to Alnylam’s pipeline products, which could be worth more than $1 billion. Alnylam says the suit is without merit.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter